CELG News and Press, Celgene Corporation From 09/26/19

Quick Take ADC Therapeutics ( ADCT ) intends to raise $200 million in an IPO of its common shares, per an F-1/A registration statement . The company is developing a pipeline of drug treatment candidates for various blood cancers and solid tumors. ADCT has shown promising trial results a...

Introduction Alexandria Real Estate Equities ( ARE ) is able to deliver faster FFO growth than other Health Care REITs through portfolio concentration in specialized office and laboratory properties in top US technology and life science markets. Rent roll-ups keep same property NOI growing a...

Quick Take Aprea Therapeutics ( APRE ) intends to raise $75 million in an IPO, according to an amended registration statement . The company is developing drug treatments for MDS and acute myeloid leukemia. APRE has achieved impressive Phase 2 trial results for its lead candidate and exp...

Listen and subscribe to the Marketplace Roundtable on these podcast platforms: iTunes/Apple Podcasts Spotify Stitcher Libsyn By Nathaniel E. Baker The Fortune Teller joins the Marketplace Roundtable Podcast to discuss his investing experience as r...

Grants include additional geographies, areas of focus and disease targets Celgene Corporation (NASDAQ: CELG) today announced an additional ten programs selected for funding under its Celgene Cancer Care Links™ program, an initiative designed to support healthcare capacity buildi...

Cold, hard cash. Getting it is frequently one of the main challenges for biotechs, particularly those with no approved products. But several of the largest biotechs currently sit on mountains of cash they can use to reward shareholders in multiple ways. The three biotechs with the biggest cash ...

As the overall market struggles to find a direction, I am trying to plan ahead and start moving some of my funds into healthcare dividend stocks that are currently at a discount compared to their peers. My first pick was CVS Health ( CVS ), but now, I am looking for a big pharma candidate and ...

Quick Take ADC Therapeutics ( ADCT ) has filed to raise gross proceeds of up to $150 million from a U.S. IPO, according to an F-1 registration statement . The firm is developing targeted antibody drug conjugates [ADCs] for the treatment of hematological malignancies and solid tumors. AD...

Should you go with the biotech that's going away or the one that's bouncing back? That's pretty much the question for investors when it comes to deciding between Celgene (NASDAQ: CELG) and Gilead Sciences (NASDAQ: GILD) . Celgene is probably only a few months away from being absorbed by ...

Quick Take Aprea Therapeutics ( APRE ) has filed to raise gross proceeds of up to $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. APRE is in Phase 3 trials for it...